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SUMMARY
Biomaterials that are similar to skeletal muscle extracellular matrix have been shown to augment regeneration in ischemic muscle. In this study,
treatment with a collagen-based matrix stimulated molecular myogenesis in an mdx murine model of necrosis. Matrix-treated animals ran ≥40%
further, demonstrating functional regeneration, and expressed increased levels of myogenic transcripts. By contrast, matrix treatment was unable
to induce transcriptional or functional changes in an MLC/SOD1G93A atrophic mouse model. In vitro, satellite cells were cultured under standard
conditions, on matrix, in the presence of myocyte debris (to simulate a necrotic-like environment) or with both matrix and necrotic stimuli. Exposure
to both matrix and necrotic stimuli induced the greatest increases in mef2c, myf5, myoD and myogenin transcripts. Furthermore, conditioned medium
collected from satellite cells cultured with both stimuli contained elevated levels of factors that modulate satellite cell activation and proliferation,
such as FGF-2, HGF and SDF-1. Application of the conditioned medium to C2C12 myoblasts accelerated maturation, as demonstrated by increased
mef2c, myf5 and myogenin transcripts and fusion indexes. In summary, the collagen matrix required a necrotic stimulus to enhance the maturation
of satellite cells and their secretion of a myogenic cocktail. Considering that matrix treatment supports myogenesis only in in vivo models that exhibit
necrosis, this study demonstrates that a necrotic environment is required to maximize matrix-mediated myogenesis.

INTRODUCTION
Skeletal muscle regeneration is a coordinated process in which
several factors are sequentially activated to maintain and preserve
muscle structure and function after injury. Muscle regeneration
occurs in four interrelated and time-dependent phases:
degeneration, inflammation, regeneration and remodeling-repair
(Carosio et al., 2011). Injury of myofibers results in rapid necrosis,
which activates a defined inflammatory response characterized by
the sequential invasion of muscle by specific inflammatory cell
populations (Tidball, 2005). This response is followed by a
regenerative phase, characterized by satellite cell (SC) activation
and the presence of regenerating fibers. The final phase is a period
during which the regenerated myofibers mature, the extracellular
matrix (ECM) undergoes remodeling and the injured muscles
functionally recover. The major roles of growth, remodeling and
regeneration are played by SCs, a quiescent population of myogenic
progenitor cells that reside between the basal lamina and
plasmalemma and are rapidly activated in response to appropriate
stimuli.
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The potential for endogenous or supplementary stem cells to
restore the form and function of damaged tissues is particularly
promising for overcoming the restricted regenerative capacity of
skeletal muscle in different pathologic conditions, including
Duchenne muscular dystrophy (DMD) and amyotrophic lateral
sclerosis (ALS). DMD is an X-linked degenerative disease in which
the absence of dystrophin expression renders the muscle fibers
more sensitive to mechanical damage. The main consequence of
dystrophin absence is that the normal regenerative capacity of
skeletal muscle cannot compensate for increased susceptibility to
damage, resulting in the replacement of muscle fibers with fibrotic
or fat tissue (Gillis, 1999; Grounds, 2008). In DMD patients, the
SC response is to replace degenerating myofibers with new
myofibers that still lack dystrophin, a cycle that proceeds and
ultimately depletes SC pools. Furthermore, the rate of myocyte
telomere loss is 14 times greater in DMD patients (Decary et al.,
2000) and their SCs appear to have a reduced potential for
proliferation (Renault et al., 2000). Ultimately, poor quality
progenitors regenerate poor quality muscle, and this muscle is still
weak and still experiences necrotic degeneration. ALS is a
neuromuscular disease that manifests as progressive motor neuron
degeneration, muscle atrophy and paralysis. This degeneration
occurs without evident signs of necrosis. Atrophic muscle maintains
fewer SCs and these SCs are dysfunctional with respect to their
abilities to proliferate and differentiate into myotubes (Mitchell and
Pavlath, 2004). ALS-derived SCs have also been observed to be
abnormally senescent and fail to fully differentiate (Pradat et al.,
2011), and ALS patients also display myopathic changes (Dupuis
and Echaniz-Laguna, 2010). Thus, in such disease states
characterized by insufficient myogenesis, SC contributions are not
optimal and may be a key reason for poor recovery and regeneration
of healthy muscle.
In skeletal muscle diseases, whether characterized by necrotic
degeneration or atrophic wasting, there is a homeostatic imbalance
793
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TRANSLATIONAL IMPACT
Clinical issue
Diseases associated with muscle loss, including Duchenne’s muscular
dystrophy (DMD), represent a huge burden to society, and ideal therapies are
not yet visible on the horizon. In such diseases, muscle loss can occur via
active, necrotic degeneration, or muscle wasting via atrophic degeneration.
Recent studies have shown that the application of biomaterials that mimic
healthy extracellular matrix can provide stem cell niches and augment skeletal
muscle regeneration.

Results
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In this study, the authors show that an injectable collagen matrix is able to
successfully regenerate skeletal muscle in a mouse model of muscle necrosis,
but not in an atrophic mouse model. This in vivo phenomenon was supported
by in vitro observations: satellite cells (SCs) that were exposed to the matrix
demonstrated an improvement in myogenesis that was maximized when SCs
were cultured on the matrix in a necrotic environment. Furthermore, matrix
and necrotic co-stimuli induced SCs to produce a cytokine cocktail containing
myogenesis-regulating factors, and this mixture accelerated myogenesis in
cultured myoblasts, and in dystrophic and ischemic muscle.

Implications and future directions
The clinical evaluation and application of biomaterials is becoming more
prevalent every day. However, to date no gene, pharmacological or cell
therapy has emerged as an ideal candidate to promote muscle regeneration.
This study has broad implications: application of a ‘healthy’ extracellular
matrix-like material has the potential to activate muscle progenitor cells and
functionally regenerate muscle. Regeneration conferred by this particular
therapy appears to be optimal under necrotic conditions, highlighting the
importance of considering the disease environment when applying
therapeutic biomaterials.

towards muscle loss and away from muscle regeneration. Despite
having genetic causes, strategies (such as gene transfer, protein
delivery and stem cell transplantation) that can shift this
equilibrium towards muscle regeneration can offer time and hope
for patients suffering from these debilitating conditions. However,
no strategy has yet emerged as ideal for enhancing muscle
regeneration in the clinic. There is a great need for regenerative
strategies that can enhance or initiate muscle regeneration (Turner
and Badylak, 2012). Although biomaterials for the regeneration of
bone, cardiovascular and nerve tissues have been extensively
investigated, little research has been performed to evaluate
biomaterial treatment for muscle diseases. The use of naturally
derived materials that mimic healthy ECM is a promising
therapeutic option and also bypasses risks associated with other
treatments, such as the need for immunosuppressant drugs,
induction of endogenous inflammatory responses and the
difficulties associated with cell culture (Kuraitis et al., 2012b). We
have recently used collagen-based matrices to augment
regeneration in ischemic skeletal muscle (Kuraitis et al., 2012a).
The objectives of this study were to: (i) evaluate the potential of a
myogenesis-augmenting collagen matrix in different muscle disease
states; (ii) characterize the interaction of this collagen matrix with
SCs; and (iii) explore the role of necrotic stimuli in matrixmediated myogenesis.
RESULTS
Matrix treatment confers functional improvements in mdx mice
Matrix or phosphate-buffered saline (PBS) was injected into the
extensor digitorum longus (EDL) muscle of mice. The EDL was
794
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chosen to receive treatment because it allows for basic animal
motility. As a model for DMD, the mdx mouse was used. Matrixtreated mdx mice were able to run distances 47% greater than shams
(P=0.02) and 40% greater than PBS-treated mice (P=0.01; Fig. 1A).
Matrix-treated mice also resisted physical exhaustion until reaching
speeds of 22 meters/second, unlike sham and PBS-treated mice
who reached exhaustion at 17 (P=0.02) and 18 meters/second
(P=0.02), respectively (Fig. 1B).
Myogenic transcripts increase with matrix treatment in mdx mice
Compared with PBS treatment, matrix treatment induced
transcription of myogenic genes in mdx muscle (Fig. 1C).
Specifically, increases were observed for crucial factors regulating
the entry of SCs into the myogenic program, proliferation and
commitment, such as Pax3 (5.9×; P=0.02), myf5 (3.5×; P=0.05),
desmin (2.3×; P=0.04) and myogenin (3.0×; P=0.02). A favorable
trend for increased transcription of Pax7 was also observed with
matrix treatment (1.7×; P=0.1). No difference in transcript levels
of the late regeneration gene encoding muscle creatine kinase
(MCK) was observed between treatments (P=0.5).
Matrix treatment does not support functional recovery or
myogenic gene transcription in a mouse model of muscle atrophy
Matrix treatment was also evaluated in the MLC/SOD1G93A mouse,
a model for ALS. No differences were observed with respect to the
maximal distances run by MLC/SOD1G93A mice (P≥0.3; Fig. 2A),
nor the speed at which exhaustion occurred (P≥0.5; Fig. 2B) among
sham, PBS and matrix treatments. Differences in myogenic
transcript levels were also not observed between treatments for
Pax7 (P=0.3), Pax3 (P=0.6), myf5 (P=0.5), desmin (P=0.3), myogenin
(P=0.2) and MCK (P=0.6; Fig. 2C).
Matrix stimulus increases primary myoblast-derived myotube
maturation and a necrotic co-stimulus increases myotube size
To investigate the effect of the matrix on SCs, primary myoblasts
were cultured on traditional collagen-I-coated dishes or matrix
substrate. SC populations were differentiated using low serum and
after 24 hours, cells were collected and analyzed. Additionally,
necrotic myocyte debris (NMD) was added to paired cultures to

Fig. 1. Functional and molecular regeneration in mdx muscle with matrix
treatment. (A,B)Matrix-treated mdx mice were able to run at greater speeds
(A) and greater distances (B) than PBS-treated littermates. (C)Early- and midstage myogenic gene transcription was also increased with matrix treatment
compared with untreated contralateral muscle. *P≤0.05 versus PBS; **P≤0.02
versus all other treatments.
dmm.biologists.org
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Fig. 2. Lack of observable regeneration in matrix-treated atrophic mice.
(A-C)Matrix treatment did not improve the running speed (A) or maximum
distance run (B) of MLC/SOD1G93A mice, nor was there any observed difference
in levels of myogenic transcripts with matrix treatment (C).

act as a necrotic stimulus. Four culture conditions were therefore
created: (i) control; (ii) NMD; (iii) matrix; and (iv) NMD plus
matrix (NMD-matrix). Morphologically, the presence of NMD
and/or matrix stimuli altered the shape of SC-derived myotubes
(Fig. 3A-D). Matrix culture, regardless of NMD stimulus,
increased the amount of generated myotubes to 13.9±1.3, which
was significant compared with control cultures and NMD stimuli
(5.0±0.9; P<0.0001; Fig. 3E). However, matrix exposure in the
presence of the necrotic stimuli increased the robustness of these
myotubes, generating myotubes that were at least 1.5× longer
(P≤0.003; Fig. 3F) and 1.2× thicker (P≤0.02; Fig. 3G). In addition
to increasing myotube frequency, matrix culture (either with or
without NMD) also supported beating and self-alignment of
myotubes (Table 1).
In a necrotic context, matrix stimulus greatly amplifies myogenic
gene transcription in satellite cell cultures
Compared with control (no NMD or matrix stimuli) cultures,
matrix exposure increased transcription of myoD by 2.2× (P=0.03;
Fig. 3I), myogenin by 1.3× (P=0.04; Fig. 3J) and mef2c by 1.2×
(P=0.02; Fig. 3K). When a necrotic stimulus was added to matrix
cultures, transcriptional myogenesis was greatly enhanced.
Compared with all other treatment conditions, simultaneous
matrix and NMD stimulation increased transcript levels of myf5
by 4.9× (P≤0.02; Fig. 3H), myoD by 13.1× (P≤0.03; Fig. 3I), myogenin
by 12.8× (P≤0.02; Fig. 3J) and mef2C by 4.5× (P≤0.04; Fig. 3J). NMD
stimulus alone did not induce any changes.
Satellite cell populations experiencing necrotic and matrix stimuli
produce a paracrine cocktail with potent myogenic effects
To investigate the potential for the matrix to induce myogenesis
via activation of paracrine signaling, supernatants collected from
SC cultures (±NMD, ±matrix stimuli) were applied to proliferating
C2C12 myoblast cultures. After 24 hours of exposure to
conditioned medium from SC cultures (or control medium), C2C12
transcription of myogenic markers was increased only when
supplemented with conditioned medium from NMD-matrix SC
cultures. Specifically, myf5 increased by 4.5× (P≤0.03; Fig. 4A),
myogenin increased by 213.4× (P≤0.02; Fig. 4B) and mef2C
increased by 191.9× (P≤0.0002; Fig. 4C). These changes were
abrogated for all markers at 48 hours (P≥0.3).
Disease Models & Mechanisms

Fig. 3. Matrix and necrotic stimuli co-activate satellite cells.
(A-D)Combinations of NMD and matrix culture conditions generated
myotubes at different stages of maturation after 24 hours. (E-G)Culture on
matrix increased the number of SC-derived myotubes (E), but addition of the
NMD co-stimulus allowed for the generation of larger myotubes (F,G).
(H-K)Myogenic gene transcription was greatest in SC cultures on matrix with
the addition of NMD. *P≤0.04 versus control; **P≤0.04 versus all other
treatments; ***P<0.0001.

At 24 hours, C2C12 cultures exposed to NMD-matrix
conditioned medium corroborated the transcriptional profile; these
myoblast cultures tended to demonstrate a greater fusion index
(3.8% versus 1.2-2.4%; P≤0.09; Fig. 4D); however, the increased
fusion index became more pronounced at 48 hours (16.1% versus
6.5-10.0%; P≤0.05; Fig. 4D). At 48 hours, all myoblast cultures were
morphologically representative of proliferation/early differentiation
(Fig. 4E-N).
Matrix and necrotic co-stimuli cause satellite cells to produce both
inflammatory and regenerative cytokines
To elucidate the paracrine factors responsible for accelerating
C2C12 myoblast maturation, supernatant collected from SC
cultures (control, NMD, matrix and NMD-matrix) was screened
using a cytokine array. NMD and/or matrix stimuli did not induce
changes in the amount of SC-produced myogenic regulatory
factors insulin-like growth factor (IGF)-I (P=0.2; Fig. 5A), IGF-II
795
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Table 1. Observed behavior of myotubes for the four culture
conditions after 24 hours
NMD +
matrix
NMD
Matrix
coControl stimulus stimulus stimuli
Stimulus
NMD

–

+

–

+

Matrix

–

–

+

+

Myotube behavior
Spontaneous beating (n=6)

0

0

4

5

Self-alignment of myotubes (n=6)

0

0

5

6

Disease Models & Mechanisms DMM

(P=0.6; Fig. 5B), IGF binding protein (IGFBP)-2 (P=0.6; Fig. 5C),
IGFBP-5 (P=0.3; Fig. 5D) or IGFBP-6 (P=0.2; Fig. 5E). NMD-matrix
stimuli increased interleukin (IL)-1α production by 2.1× (P≤0.05;
Fig. 5F), but did not alter IL-1β production (P=0.5; Fig. 5G). Both
NMD and NMD-matrix conditions increased IL-4 by 2.7× and 2.0×,

respectively (P≤0.003; Fig. 5H). IL-6 was increased by 4.7× only
under NMD-matrix conditions (P≤0.01; Fig. 5I). No conditions
induced changes in production of IL-10 (P=0.2; Fig. 5J) or tumor
necrosis factor-α (TNF-α; P=0.2; Fig. 5K). Monocyte chemoattractant protein-1 (MCP-1) trended towards a 23% reduction in
all treatments, compared with control (no NMD, no matrix stimuli)
conditions (P≤0.06; Fig. 5L). Both NMD and NMD-matrix
conditions increased fibroblast growth factor-2 (FGF-2) levels by
2.8× and 3.3×, respectively (P≤0.02; Fig. 5M). Only NMD-matrix
conditions increased levels of hepatocyte growth factor (HGF; by
1.5×; P≤0.02; Fig. 5N) and stromal cell-derived factor-1 (SDF-1; by
1.5×; P≤0.05; Fig. 5O).
DISCUSSION
In dystrophic mice, collagen matrix treatment stimulated
myogenesis, probably contributing to the observed functional
improvements. It is important to note that the model was unilateral;
therefore, the functional results probably underestimate the
potential of this treatment should both legs receive treatment. The
Fig. 4. Paracrine effects of SCs after exposure to matrix
and necrotic cell debris. (A-C)The addition of conditioned
medium from SC cultures exposed to matrix and NMD
accelerated the transcription of myf5 (A), myogenin (B) and
mef2c (C) in SC at 24 hours, compared with all other
conditioned medium treatments and with standard
myoblast differentiation conditions with DM. (D)At 48
hours, there was an increase in cell fusion of myoblasts
cultured with conditioned medium from matrix-NMD SC
cultures. (E-N)Representative images of differentiating
myoblasts at 24 hours (E-I) and 48 hours (J-N). Cells are
visualized with anti-laminin (green) and nuclei with Hoechst
(blue) stains. *P≤0.09 versus all other treatments at 24
hours; **P≤0.05 versus all other treatments at each time
point; ***P≤0.0002 versus all other treatments at 24 hours.
Scale bars: 100 μm.
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Fig. 5. Identification of paracrine factors
produced by satellite cells after exposure
to matrix and necrotic cell debris for 24
hours. (A-E)Matrix-NMD stimuli did not
induce changes in the production of IGF-I (A),
IGF-II (B), IGFBP-2 (C), IGFBP-5 (D) or IGFBP-6
(E). (F-L)Changes in production of some
inflammatory cytokines were observed with
matrix and NMD exposure: IL-1α (F), IL-1β (G),
IL-4 (H), IL-6 (I), IL-10 (J), TNFα (K) and MCP-1
(L). (M-O)Matrix and NMD co-stimuli
enhanced the production of regenerative
cytokines FGF-2 (M), HGF (N) and SDF-1 (O).
**P≤0.02 versus treatments without NMD
stimulus; ***P≤0.05 versus all other
treatments; ****P≤0.06 versus all other
treatments.

mid-stage myogenic gene encoding myogenin was increased, as
were the early-stage genes encoding desmin and Myf5. SC marker
Pax3 was also increased, but interestingly the SC marker Pax7 was
not. Pax3 and Pax7 have similar roles in specifying myogenic cell
fate and both may be used to identify SCs (Horst et al., 2006; Relaix
et al., 2006). It is possible that the increase in only Pax3 mRNA
can be attributed to a subpopulation of SCs. A new myogenic
Pax3+Pax7- population, found in the interstitium and not the basal
lamina, has previously been identified (Kuang et al., 2006). It has
also been reported that Pax3 is expressed in quiescent muscle
satellite cells in a subset of muscles and it plays an important role
in regulating the entry of satellite cells into the myogenic program
(Buckingham, 2007; Relaix et al., 2006). Thus, Pax3 plays a distinct
role in this context, as it is expressed in proliferating SCs before
they exit the cell cycle (Conboy and Rando, 2002), thereby
Disease Models & Mechanisms

suggesting that Pax3+ SC proliferation may be greater in matrixtreated muscles. MCK, a late marker of myogenesis, was not
increased with matrix treatment, implying that the observed
myogenesis had not yet reached a stage of late maturation.
Treatment of ischemic muscle – another disease state characterized
by necrotic degeneration – with the same collagen matrix also
resulted in increased expression of myogenic genes, but not in Pax7
transcripts (Kuraitis et al., 2012a). It is curious that, despite the
striking functional improvements and molecular myogenesis in the
mdx and ischemic models, no indication of myogenesis was evident
in atrophic animals. The obvious differences between the models
are the muscle microenvironment and the modes by which muscle
is lost: dystrophic muscles and ischemic muscles are characterized
by degeneration of necrotic myofibers and inflammation, whereas
atrophic muscles do not present significant amounts of necrotic
797
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or non-apoptotic dead myocytes. The difference between the
ability of these microenvironments to modulate myogenesis was
further explored with in vitro studies.
Exposure to a collagen matrix improved the number of SCgenerated myotubes; however, the addition of a necrotic stimulus
increased their size and induced functional beating, something that
is not typically seen in SC cultures until 2-3 days after
differentiation. Similarly, matrix exposure induced mild increases
in myogenic genes, but in a necrotic context the matrix markedly
amplified transcription of a greater number of myogenic genes. We
have recently demonstrated that this collagen matrix has an
inherent potential for myogenesis: when it was used as a substrate
for the culture of pluripotent embryonic stem cells, multinucleated
Pax3+ populations were generated that also expressed myogenin
and myf5 (Kuraitis et al., 2012a). This matrix also mimics skeletal
muscle elasticity. ECM elasticity is one of the key parameters that
govern progenitor cell differentiation (Engler et al., 2006), as
maximal myoblast-to-myotube differentiation has been shown to
occur when the substrate’s elasticity mimics that of native skeletal
muscle (Engler et al., 2004; Gilbert et al., 2010). The novelty of our
study is that matrix and necrotic co-stimuli aggrandize myogenesis
from SCs. Dehne and colleagues have shown that exposure to
muscle cell debris activates myoblasts and signals for the production
of regenerative factors (Dehne et al., 2011). Thus, a necrotic
mechanism – in particular, direct SC-necrotic myocyte contact –
may be necessary in order to achieve maximal myogenesis with
collagen matrix treatment. Because the DMD phenotype is
exacerbated by the lack of functional glycoprotein complexes to
link the ECM and cytoskeleton (Straub and Campbell, 1997), the
in vitro observations support the hypothesis that provision of a
material that potentially mimics healthy ECM may at least partially
compensate and support robust regeneration in mdx mice.
Muscle turnover and regeneration is a complex process and
highly coordinated among myocytes, progenitor cells and
inflammatory cells. Because of this cross-talk, it is difficult to
identify the sources of regenerative signals. Myotube incubation
with muscle cell debris appears to produce autocrine and/or
paracrine factors, because application of this supernatant alone was
able to activate other myotubes that were not exposed to cell debris
(Dehne et al., 2011). Application of conditioned medium from SC
cultures (±NMD, matrix stimuli) to myoblasts revealed that
exposure to both the matrix and necrotic stimuli generated a
paracrine cocktail that could induce myogenesis in myoblasts 24
hours after exposure. The acceleration of myf5, myogenin and mef2c
transcription was no longer apparent at 48 hours, but increased
cell fusion was maintained at the later time point. It would have
been interesting to observe these effects later into stages of myotube
maturation, but after 48 hours the cell media could not be replaced
with fresh media of known contents and thus the experiment could
not be continued beyond this time point.
Arrays were used to identify paracrine factors whose presence
might explain why the conditioned medium from NMD-matrix
SC cultures can accelerate myogenesis. Surprisingly, treatment
conditions did not generate different amounts of IGF-I, IGF-II or
their binding proteins. IGFs and their binding proteins have
important and known roles in myogenesis (Duan et al., 2010).
SCs exposed to both stimuli produced IL-1α, IL-4 and IL-6. Under
pro-inflammatory stimuli, SC-derived myocytes naturally produce
798
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inflammatory interleukin cytokines (Nagaraju et al., 1998). TNFα is considered one of the most degenerative cytokines, so it may
be favorable that TNF-α levels were not elevated. The presence
of IL-4 is required for myoblast fusion with myotubes and its
absence leads to myotubes of reduced size (Horsley et al., 2003).
IL-6 is produced by SCs and growing myofibers and its absence
reduces myoblast proliferation and migration (Serrano et al.,
2008). Thus, SCs exposed to a combination of matrix and necrotic
stimuli increase their production of inflammatory cytokines that
have defined roles in myoblast function and maturation. The
chemokine MCP-1 is important for recruitment of mononuclear
cells post-injury (Chazaud et al., 2003) and MCP-1−/− animals
display impaired regeneration (Shireman et al., 2007). However,
SCs appear to produce MCP-1 immediately after activation and
emigration from quiescence, and this production tapers off over
time (Chazaud et al., 2003). Given that SCs appeared to mature
under NMD or matrix stimuli and that the control conditions
were least supportive of SC maturation, it is plausible that the
precursor cells in control conditions produced greater amounts
of MCP-1 because they are in a more primitive stage of the
myocytic lineage and have not yet matured to a phenotype with
ablated MCP-1 production.
In addition to inflammatory cytokines, skeletal muscle
regeneration requires coordinated growth factor signals (Turner
and Badylak, 2012). Of the cytokines with known roles in
myogenesis, the production of HGF, FGF-2 and SDF-1 was greatly
increased by SCs in response to NMD-matrix co-stimuli. HGF is
a potent growth factor produced in an autocrine fashion, and is
capable of stimulating quiescent SC activation (Tatsumi et al., 1998)
and proliferation (Sheehan et al., 2000). FGF-2 is also produced by
muscle progenitor cells (Joseph-Silverstein et al., 1989) and has a
strong ability to induce SC proliferation (Deasy et al., 2002).
Furthermore, HGF and FGF-2 synergistically increase SC
proliferation (Sheehan and Allen, 1999). SDF-1 is a chemoattractant capable of recruiting a variety of progenitor cell
populations, including SCs (Miller et al., 2008; Ratajczak et al.,
2003). It has been suggested that based on its ability to attract SCs,
SDF-1 might play a bimodal role and function to recruit cells both
to a quiescent niche and also to sites of injury or regeneration
(Miller et al., 2008). Together, the cytokines produced by SCs under
NMD-matrix conditions are supportive of myoblast activation,
proliferation and maturation, as demonstrated by the accelerated
myogenesis in C2C12 myoblast cultures in the presence of this
cytokine cocktail.
This study employed a collagen-based matrix containing
chondroitin sulfate-C, which has physical properties similar to those
of native, healthy skeletal muscle. It is noteworthy that provision
of a matrix containing only two ECM components is able to support
and accelerate myogenesis. Future studies will be needed to better
understand how the ECM changes in disease states and how we
can best replicate ‘healthy’ ECM in order to facilitate recovery and
regeneration. When designing therapeutic biomaterials, such
studies will probably exploit specific regenerative cues that already
exist in the ECM in order to best harness and benefit from
endogenous cues for regeneration (Kuraitis et al., 2012b).
The conclusions of this study are multiple: (i) treatment with a
collagen-based matrix can augment myogenesis, but this
regeneration is context-dependent and may require a necrotic
dmm.biologists.org
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environment as a mechanism for achieving maximum regeneration;
(ii) under necrotic conditions, the matrix superactivates SC
populations to mature and also to produce a potent myogenic
cocktail of secreted proteins; and (iii) instead of attempting to
modulate necrosis and inflammation, this study provides a novel
therapy that can harness the constant necrosis that occurs in DMD
and use it as a ‘Trojan Horse’ for regeneration that translates into
improved function. Perhaps more globally, this study also highlights
that the disease state must be carefully considered when applying
therapeutic biomaterials, because the matrix presented in this study
only induced myogenesis in states of active necrosis and failed to
induce myogenesis in an atrophic model.

Disease Models & Mechanisms DMM

MATERIALS AND METHODS
Unless otherwise specified, all materials and reagents were obtained
from Sigma-Aldrich (Schnelldorf, Germany).
Matrix preparation
Collagen matrix was prepared on ice, as previously described
(Kuraitis et al., 2011). N-(3-dimethylaminopropyl)-N⬘ethylcarbodiimide hydrochloride (EDC) and N-hydroxysuccinimide
(NHS) were mixed in a 1:1 molar ratio (13 mM) in 2-(Nmorpholino) ethanesulfonic acid (MES) buffer. This EDC/NHS
crosslinker was added to a solution of 1% (w/v) type I collagen
(Nippon Ham, Tskuba, Japan) and 40% (w/v) chondroitin sulfateC (CSC; Wako Chemicals, Osaka, Japan). The solution was diluted
with PBS before adjusting the pH to 7.2±0.2. The final
concentrations of collagen and CSC were 0.59 and 2.4% (w/v),
respectively. For in vivo use, the matrix was kept on ice and
transferred to a cold syringe immediately prior to use. For in vitro
use, 150 μl was spread onto 6-cm tissue culture polystyrene plates
before being thermogelled at 37°C and rinsed with PBS before cell
application.
Animal model
The animals were housed in a temperature-controlled (22°C) room
with a 12-hour light-dark cycle. All of the mice were maintained
according to the institutional guidelines of the animal facilities of
DIEM-National Institute of Health-Italy.
Two mouse lines were used to evaluate the potential of the matrix
for myogenesis. The well-characterized mdx mouse (Willmann et
al., 2012) was used as a model for DMD. The MLC/SOD1G93A
mouse, recently characterized (Dobrowolny et al., 2008), was used
as a model for muscle atrophy and ALS. Given its ability to represent
animal motility and muscle function, the EDL muscle was chosen
to evaluate matrix treatment. The left EDLs of 1-month-old male
mdx and 4-month-old female MLC/SOD1G93A mice were surgically
exposed and received a 5-μl injection of either PBS or matrix.
Treadmill tests were performed at 6 weeks for mdx mice and at 6
months for MLC/SOD1G93A mice. After collection of treadmill data,
animals were sacrificed and EDL muscles were harvested, flashfrozen in liquid nitrogen and stored at −80°C.
Functional analysis with a forced treadmill test
To assess the function of treated muscles, mice were subjected to
a forced treadmill protocol. They were conditioned to the treadmill
process for 1 week prior to final testing at an incline of 0° for 5
minutes at 5 meters/second and 5 minutes at 10 meters/second.
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Animals that did not maintain the treadmill speed received a shock
of 0.5 mA. The maximal test of exhaustion was modified from a
published method (Ferreira et al., 2008). In brief, the treadmill
speeds increased every 3 minutes at a rate of 3 meters/minute.
Animals were removed from the treadmill when they could no
longer manage to return to the treadmill from the shock platform.
Total distance and speed at which exhaustion occurred were
recorded. The same parameters were also measured on untreated
(sham) animals for both models.
C2C12 myoblast culture
All cells in culture were maintained at 37°C in a humidified
incubator with 5% CO2. C2C12 myoblasts were used between
passages 6 and 9. Cells were maintained on 20-cm tissue culture
dishes in growth medium (GM) consisting of DMEM supplemented
with 20% fetal bovine serum (FBS), penicillin/streptomycin and
4 mM L-glutamine. Upon reaching ~85% confluence, cells were
differentiated by replacing their GM with differentiation medium
(DM), which is equivalent to the GM formulation but containing
only 2% FBS. To store amplified cells, 1×105 C2C12 myoblasts were
suspended in GM and DMSO in a 9:1 ratio and frozen at −80°C.
Necrotic myocyte debris preparation
Confluent C2C12 myoblasts were differentiated into early-stage
myotubes for 24 hours. NMD was prepared by manually scraping
myotubes, centrifuging and storing the collected debris at −80°C
at a concentration of 2×106 cells/100 μl PBS. Application of NMD
to other cell populations allows for the observation of interactions
that stem from direct cell contact with dead myocytes (Dehne et
al., 2011). Prior to application in culture, NMD was confirmed to
contain non-viable cells by examination under a light microscope
using Trypan Blue dye.
Satellite cell isolation
Wild-type C57 mice, 3-4 weeks of age, were sacrificed and the
hindlimb muscle was harvested under sterile conditions. Muscles
were minced and enzymatic digestion using collagenase and dispase
was performed as previously described (Musarò and Barberi,
2010). After digestion, the solutions were pre-plated on tissue
culture dishes to remove contaminating fibroblasts, for 45 minutes
and then for 30 minutes. SCs were amplified on collagen-I-coated
plates in growth medium consisting of DMEM supplemented with
20% horse serum, penicillin/streptomycin, L-glutamine (4 mM) and
3% chick embryo extract. One day after isolation, cells were lifted
using 0.25% trypsin, pre-plated again for 30 minutes and re-plated
on new collagen-coated dishes. Cells were washed with PBS and
the growth medium changed every other day.
Satellite cell differentiation
After 4-5 days, 6-8×105 cells could be collected from the primary
cultures derived from one mouse and 8×104 SCs were plated in
3 ml differentiation medium on 6-cm dishes coated with collagen
I [used as standard SC culture substrate (Musarò and Barberi,
2010)] or matrix. Cultures then received either 100 μl of NMD or
100 μl of PBS. Ultimately, four culture conditions were created: (i)
standard culture conditions; (ii) NMD stimulus; (iii) matrix
substrate stimulus; and (iv) NMD-matrix stimuli. After 24 hours
in culture, cell observations were recorded and cells imaged. Then
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the cells were thoroughly rinsed with calcium- and magnesiumfree PBS (CMF) to remove dead cells and NMD and immediately
frozen at −80°C. Cell images were analyzed using ImageJ 1.32s
(National Institutes of Health, Bethesda, MD) for the number of
myotubes per field-of-view (FOV), and their lengths and widths.
Width was defined as the maximum width of a myotube. Based on
myotube morphology, this measurement was taken at the center,
approximately equidistant from either end. The medium from these
24-hour cultures (for all four conditions) was flash-frozen in liquid
nitrogen and stored at −80°C to be used as conditioned medium
in subsequent C2C12 studies.
C2C12 myoblast differentiation
As described, C2C12 myoblasts were differentiated into early-stage
myotubes using low serum medium. Cultures were maintained on
3-cm dishes. Upon ~85% confluence, GM was replaced either with
3 ml DM or with 2 ml DM + 1 ml of conditioned medium from
SC cultures (four conditions tested: control, NMD, matrix, or
NMD-matrix). Upon harvest at 0, 24 or 48 hours, cells were rinsed
with CMF and stored at −80°C for RNA extraction. A subset of
differentiating myoblasts was prepared for fusion index analysis.
Cells were fixed with 70% methanol for 20 minutes, blocked for 45
minutes with 10% goat serum in CMF, incubated for 2 hours at
room temperature with 1:200 goat anti-laminin in 1.5% goat serum
and then incubated for 45 minutes at room temperature with 1:2000
mouse anti-goat Alexa Fluor 488 (Invitrogen, Burlington, Canada)
and 1:1000 Hoechst 33342 stain. Before and after each incubation
step, cells were washed for 2×10 minutes with PBS containing 1%
BSA/ and 0.2% Triton X-100. Cells were imaged using an inverted
Axioskop 2 Plus microscope (Zeiss, Oberkochen, Germany) and
images were processed using Axiovision 3.1 software (Zeiss). The
fusion index was calculated as the percentage of nuclei present in
multinucleated cells.
RNA preparation and quantitative PCR analysis
Total RNA was isolated from homogenized muscle and manually
scraped cell cultures using TRIzol reagent (Invitrogen) as
previously described (Rio et al., 2010). RNA was converted to
cDNA using the QuantiTect Reverse Transcription kit according
to the manufacturer’s instructions (Qiagen, Milan, Italy). The
reagent proportions as specified by the manufacturer were used
for each 1 μg of RNA. cDNA concentrations were raised to 10
ng/ml with nuclease-free water and stored at −20°C. qPCR
reactions were prepared with 5 μl cDNA, 6.25 μl nuclease-free
water, 12.5 μl TaqMan PCR Master Mix (Applied Biosystems,
Foster City, CA) and 1.25 μl TaqMan Probe (Applied Biosystems).
TaqMan Probes were used for murine β-actin, desmin, GAPDH,
MCK, mef2C, myoD, myogenin, myf5, Pax3 and Pax7. The
reaction was performed using an Applied Biosystems RealPlex
7500 Fast Real Time system and software. Relative gene expression
was quantified using the ΔΔCt method, as described (Livak and
Schmittgen, 2001). Transcripts from treated muscles were
expressed relative to those in untreated muscles (using
housekeeping genes encoding GAPDH for mdx mice and β-actin
for MLC/SODG93A mice; n=4). Transcripts from cultured cells
were expressed relative to control treatments (using housekeeping
genes encoding GAPDH for C2C12 myoblast cultures and β-actin
for SC cultures; n=4-6).
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Cytokine arrays
Conditioned medium collected from SC cultures was analyzed
using a cytokine array according to the manufacturer’s instructions.
Custom cytokine arrays (RayBioTech, Norcross, GA) were used to
analyze protein levels of IGF-1, IGF-II, IGFBP-2, IGFBP-5, IGFBP6, IL-1α, IL-1β, IL-4, IL-6, Il-10, TNFα, MCP-1, FGF-2, HGF and
SDF-1.
Statistical analysis
All experiments were performed with n=4, except SC cultures and
cytokine arrays, which were performed with n=6. Data between
two experimental conditions were analyzed using a Student’s t-test
and data between multiple groups was analyzed using a one-way
analysis of variance with Tukey’s post-hoc using Prism 4.0
(GraphPad, La Jolla, CA).
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